Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

Autor: J. De Castro Carpeno, A Franceschetti, D Bell, Y Escobar Álvarez, A Drago
Rok vydání: 2021
Předmět:
Cancer Research
medicine.medical_specialty
Consensus
Databases
Factual
Vomiting
Nausea
medicine.drug_class
medicine.medical_treatment
Antineoplastic Agents
Dexamethasone
Carboplatin
03 medical and health sciences
chemistry.chemical_compound
MASCC/ESMO guidelines adherence
0302 clinical medicine
Neurokinin-1 Receptor Antagonists
Internal medicine
medicine
Humans
Serotonin 5-HT3 Receptor Antagonists
Antiemetic
Anthracyclines
030212 general & internal medicine
Cyclophosphamide
NK1RA-based regimens
Cisplatin
Chemotherapy
business.industry
Cancer
General Medicine
medicine.disease
Oncology
chemistry
Spain
Highly emetogenic chemotherapy
Health Care Surveys
030220 oncology & carcinogenesis
Chemotherapy-induced nausea and vomiting
Antiemetics
Guideline Adherence
medicine.symptom
business
Research Article
medicine.drug
Zdroj: Clinical & Translational Oncology
ISSN: 1699-3055
1699-048X
DOI: 10.1007/s12094-021-02623-8
Popis: Purpose Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting in Spain. Methods A representative panel of cancer specialists was asked to collect information about the antiemetic treatments provided to patients receiving chemotherapy. Records formed part of the Global Oncology Monitor© database (Ipsos Healthcare, London, UK). Chemotherapy data were extrapolated using Ipsos Healthcare’s projection methodology. Results A total of 73 experts were finally included. Data from 9519 patients, estimated to be representative of 202,084 patients, were collected. HEC (and carboplatin-based chemotherapy) was administered to 73,118 (36%) patients, cisplatin-based therapy being the most frequent treatment (n = 34,649, 47.38%). Neurokinin-1 receptor antagonists (NK1RAs) alone or in combination were used as prophylaxis for CINV in 14,762 (20%) patients, while the combination of NK1RA with 5-hydroxytryptamine-3 receptor antagonist (5-HT3RAs) and dexamethasone as recommended by the international guidelines was used in 5849 (8%) patients only. No antiemetic prophylaxis was administered to 8.46% of the patients receiving HEC (n = 6189). Physicians classified cisplatin-, anthracycline-cyclophosphamide (AC-), and carboplatin-based regimens as HEC in 63%, 22% and 4% of the cases, respectively. Conclusions The use of NK1RA-containing regimens for CINV prevention in patients treated with HEC was less than expected, suggesting poor adherence to international antiemetic guidelines.
Databáze: OpenAIRE
Externí odkaz: